EPRX Eupraxia Pharmaceuticals Inc

H.C. Wainwright reiterated $EPRX at Buy-$11 after $AZN and $AMGN reported full results from the positive Phase 3 CROSSING trial of TEZSPIRE in EoE. REGN - SNY PHAT TRAX BMY ABBV H.C. Wainwright said -- While the results introduce another potentially effective biologic competitor into the EoE treatment landscape, we do not view the data as diminishing the opportunity for EPRX's EP-104GI. In fact, we believe the magnitude of TEZSPIRE's histologic benefit relative to its more modest placebo-adjusted symptom improvement reinforces the opportunity for differentiated therapies that can deliver durable improvements in both symptoms and tissue health. We continue to view EP-104GI's potential to provide sustained efficacy following a single administration as an attractive differentiator versus biologics requiring chronic treatment. With the placebo-controlled Phase 2b RESOLVE interim analysis expected in December, we believe EPRX offers a favorable risk-reward ahead of a meaningful catalyst.

$EPRX reached its RESOLVE Phase 2b enrollment target of 120 patients, a key milestone for its EP-104GI EoE trial.

$EPRX (Eupraxia, clinical-stage biotech testing EP-104GI, injected into the esophageal wall for eosinophilic esophagitis) says in-house reviews of unblinded Phase 2b RESOLVE data found the 120-patient sample size needs no increase; patient 120 was dosed Oct. 12. Market value ~$342.3M at $6.59 (16:00 ET, Oct. 14, 2026); cash $80.6M at Dec. 31, 2025. But a company team ran the reviews and gave no efficacy numbers. Interim on the first 60 Phase 2b patients at 6 months is due December 2026.